New Japanese encephalitis (JE) vaccine wins WHO prequalification

   PATH and China National Biotec Group Co., Ltd. (CNBG) announced that SA 14-14-2, a live, attenuated Japanese encephalitis (JE) vaccine, won WHO prequalification.  The action also represents the first time a vaccine produced by a Chinese manufacturer has achieved prequalification. The vaccine is manufactured by Chengdu Institute of Biological Products Co., Ltd. (CDIBP), a subsidiary of CNBG. With funding from the Bill & Melinda Gates Foundation, PATH “led a series of pivotal clinical trials to establish the immunogenicity and safety of the vaccine in at-risk children and provided technical and financial support to help CDIBP meet the international manufacturing standards required for WHO prequalification.” Steve Davis, PATH president and CEO, commented, “This milestone brings the world within reach of an audacious goal: the elimination of a devastating disease through expanded access to an affordable and lifesaving vaccine. Our groundbreaking collaboration with leading Chinese partners also helped lay the foundation for reshaping global vaccine supply, pricing, and accessibility through increased competition. This milestone signals China’s rising importance as a global supplier of high-quality vaccines for the most vulnerable children in the world.”

Read more about PATH’s JE Project.